Consultancy & Advisory Services

US-based economic consulting firm with published outcomes and cost-effectiveness analyses on esketamine treatment pathways relevant to payer decision-making and market access strategy.

The Association for Prescription Psychedelics is an active organisation with a live official website, current news updates, and stated leadership and contact details. It presents itself as an industry voice for prescription psychedelic medicine, focused on advocacy, policy engagement, and regulatory coordination rather than a consumer product or one-off event. Its work aligns most closely with adjunct industries because it supports the development, access, and policy environment around psychedelic medicines.

Consultant Agency for Psychedelic Services (CAPS) is a UK-based advisory practice led by Dr Ben Sessa, providing consultancy for individuals, clinics, companies, and investors developing psychedelic and medical-cannabis services.

Full-service CRO with in-house research units in Sweden and the Netherlands. Psychedelic-specific evidence remains weaker than its general CNS and early-phase site-network capability.

Economic and strategy consultancy with life sciences advisory services, including published analysis on the evolving psychedelic therapeutics landscape and market implications.

Clinilabs Drug Development Corporation is the only global full-service contract research organisation (CRO) exclusively focused on central nervous system drug development, with over 25 years of experience managing Phase 1–3 trials across psychiatric, neurological, and substance-use disorders. It partnered with Cybin to conduct the first-in-human Phase 1/2a trial of CYB003, a deuterated psilocybin analog for major depressive disorder, obtaining DEA Schedule I licensing to support this psychedelic study.

Delphi is a psychedelic healthcare consultancy focused on responsible integration into mainstream care. Led by Lia Mix and a cross-sector team, Delphi supports healthcare providers, investors, government agencies, and psychedelic organisations with strategy, education, and implementation guidance across regulation, delivery, and reimbursement. A major Delphi initiative is IHPI (Ibogaine Healthcare Policy Institute), a neutral, evidence-based, implementation-focused institute that develops coverage playbooks, health-economics models, and delivery blueprints for safe ibogaine adoption. Delphi also leads HOPE (Health Outcomes and Psychedelic Economics), a collaborative effort to generate independent economic evidence that can inform payer policy and broader healthcare access decisions.

Finland-based consultancy and co-production practice led by social scientist Aleksi Hupli. Drugventures provides businesses, universities, non-profits, professionals and private individuals with research-informed advice on psychedelics, cannabis, cognitive enhancement and drug policy, including emerging-market and country analysis, lectures, communications and content production, and individual coaching.

Commercial real-world data products and linked evidence assets used in life sciences research and regulatory support.

Katogen is an operator-led biopharma consulting and strategy firm advising growth-stage life sciences companies, drawing on 35+ years of operator experience.

Global strategy consultancy with US/EU healthcare practices and published analysis on psychedelic treatment pathways, funding dynamics, and commercialization implications.

Global commercialization and market access advisory firm with published commentary on positioning psychedelic medicines within biopharmaceutical development frameworks.

US psychedelic drug-development consultancy providing clinical trial roadmaps, regulatory planning, and operational integration frameworks for emerging neuropsychiatry programs.

UK-based psychedelic-focused consultancy offering strategic and business development services, education curriculum design, and partner collaborations for organizations in the sector.

US-based cannabis and psychedelic consulting firm providing licensing, compliance, SOP, and operational support alongside strategic planning for psychedelic ventures.

Psychedelic integration and advisory practice offering preparation/integration support and explicit psychedelic business consulting and coaching for practitioners and service builders.

Psychedelic Alpha (Pα) is an independent, data-driven psychedelic media, research and advisory platform, founded in 2020 by Josh Hardman and based in London. It publishes the widely read weekly Psychedelic Bulletin newsletter alongside closely followed trackers of psychedelic drug development and of psychedelic law and policy, and provides advisory and consultancy services to investors, philanthropists, government agencies, startups and established firms. It is known for cutting through hype to surface what matters in the development, regulation and commercialisation of psychedelic medicines.

US-based consultancy supporting hospitals and clinics with psychedelic and ketamine service implementation, including strategic planning, staffing, protocol setup, and quality systems.

Psychedelic Science Institute is a real, currently operating organisation that describes itself as a clinical trial and treatment network for psychedelic medicine. Its site and a 2025 press release both state that it runs TRIP Clinics in California and supports clinical research and training. This fits best under consultancy and advisory services rather than software, creative, or legal work.

Psychedelic-focused consulting practice led by Scott Gagel, PA-C, offering clinically informed guidance, assessment, and consultation services for individuals exploring plant-medicine treatment pathways.

Target Health Inc. is a New York-based full-service contract research organization (CRO) and clinical trials software company. Known for its proprietary electronic data capture system and a 100% success rate on FDA market applications, it provides regulatory affairs, clinical research management, biostatistics, and paperless trial platform services to pharmaceutical and biotech sponsors.

An independent clinical research organization (CRO) founded in 1977 and headquartered in Rockville, Maryland, specializing in the design and management of clinical trials. Emmes has expertise across therapeutic areas including ophthalmology, neurology, and immunology, providing biostatistics, data management, and regulatory support for academic and government-sponsored trials.

Purpose-led healthcare consultancy focused on integrating psychedelic-assisted therapy into health systems, with explicit services across strategic planning, implementation, reimbursement, and go-to-market execution.

Miami-based boutique consulting firm supporting cannabis and psychedelic organizations with product strategy, operational optimization, and capability development.

Global full-service CRO with a dedicated psychedelic center of excellence and stated experience supporting industry-sponsored psychedelic programs across psychiatric indications.